SCHEMBL9829030

SCHEMBL9829030

CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)NCC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
PTGS2 P35354 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
ECE1 P42892 1/20 0.47
MME P08473 2/20 0.42
ACE P12821 2/20 0.42
CPA1 P15085 1/20 0.42
ACE2 Q9BYF1 1/20 0.42
DPP4 P27487 1/20 0.40
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
PTGS1 P23219 1/20 0.37
GSTK1 Q9Y2Q3 1/20 0.37
DPP8 Q6V1X1 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
CTRB1 P17538 2/20 0.36
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9829015 1.00 LMNA (0.48) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL30123324 0.88 ALDH1A1 (0.47) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL16774718 0.88 LMNA (0.47) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL16774717 0.88 LMNA (0.47) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL29608926 0.86 MME (0.46) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL21261769 0.85 LMNA (0.52) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL31410871 0.85 ALDH1A1 (0.39) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL29498254 0.85 LMNA (0.44) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL30051145 0.85 MME (0.54) LMNAALDH1A1MAPTPTGS2TDP1
SCHEMBL29460679 0.83 ALDH1A1 (0.43) LMNAALDH1A1MAPTPTGS2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP claimed
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 US disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 US disclosed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP LMNA 1538/4885ALDH1A1 3596/4885MAPT 3330/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD LMNA 3184/4885ALDH1A1 4110/4885MAPT 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.